Hydroxyzine (Atarax) Should Be Avoided for Agitation in Elderly Patients
Hydroxyzine should not be used for managing agitation in elderly patients. The most recent 2025 geriatric emergency medicine guidelines explicitly excluded antihistamines from their systematic review of agitation management due to strong evidence that these agents should be avoided because of their anticholinergic properties 1. When pharmacologic intervention is necessary for severe agitation in older adults, oral quetiapine has the best safety profile among studied medications 1.
Why Hydroxyzine Is Inappropriate
Guideline-Based Exclusion
The 2025 Geriatric Emergency Department Guidelines 2.0 systematically reviewed medications for severe agitation in older adults (≥65 years) and deliberately excluded studies comparing antihistamines because these agents should be avoided due to anticholinergic properties 1. This represents the current expert consensus from over 50 geriatric emergency medicine specialists.
FDA Labeling Concerns
The FDA label for Atarax explicitly warns that 2:
- "Sedating drugs may cause confusion and over sedation in the elderly"
- Elderly patients should be started on low doses and observed closely
- No controlled studies have adequately defined dosing differences between elderly and younger patients
- Greater caution is needed due to decreased hepatic, renal, or cardiac function in older adults
Cognitive Impairment Risk
Research demonstrates hydroxyzine causes significant cognitive impairment in elderly patients. Even a single 25 mg dose can cause sedation, though it preserves memory better than benzodiazepines 3. However, morning doses cause more prominent impairment across all cognitive tasks compared to evening doses 4, and daytime somnolence persists even with nighttime dosing 5.
Recommended Alternatives for Elderly Agitation
First-Line Approach
Always attempt nonpharmacologic interventions first (person-centered communication, sensory therapy) as antipsychotics and anxiolytics pose significant risks in older adults 1.
When Pharmacologic Treatment Is Necessary
Based on the 2025 systematic review analyzing adverse events in elderly patients with severe agitation 1:
Preferred option:
- Oral quetiapine - demonstrated the best safety profile among all studied medications
- Use the lowest effective dose
- Oral administration reduces adverse events compared to IV/IM routes
Avoid:
- Benzodiazepines (especially midazolam) - elevated risk of serious adverse events without efficacy gains
- Hydroxyzine and other antihistamines - anticholinergic burden
- Higher doses - dose-dependent increase in adverse events observed for lorazepam, droperidol, and quetiapine
Critical Safety Data
Serious adverse events occurred in 16.8% of older adults who received antipsychotic or anxiolytic medications for agitation, including respiratory depression, prolonged QTc, arrhythmia, hypotension, falls, delirium, and mortality 1.
Clinical Pitfalls to Avoid
Do not extrapolate from younger adult data - older adults require lower doses and greater tolerance of time-to-sedation to reduce adverse events 1
Do not use IV/IM routes unless absolutely necessary - these significantly increase adverse event risk compared to oral administration 1
Do not assume nighttime dosing eliminates hydroxyzine's risks - while evening dosing may reduce some psychomotor effects 6, daytime somnolence persists and cognitive impairment remains significant 4, 5
Do not combine with other CNS depressants - hydroxyzine potentiates effects of narcotics, analgesics, and barbiturates; dosages of concomitant CNS depressants must be reduced 2